MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$43,366K
Free Cash flow
-$115,558K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from sales and maturiti...
Stock-based compensation expense
Accrued restructuring costs
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accrued clinical and research an...
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2025-06-30
Stock-based compensation expense
12,134
Amortization of operating lease right-of-use assets
1,080
Prepaid expenses and other current assets
-316
Other non-current assets
-5,311
Operating lease liabilities
-6,447
Accounts payable
6,533
Impairment of long-lived assets
10,197
Depreciation
712
Accretion on investments in marketable securities
1,478
Accrued restructuring costs
10,646
Accrued expenses and other current liabilities
-8,590
Accrued clinical and research and development expenses
-11,721
Acquired in-process research and development
665
Net cash used in operating activities
-115,077
Proceeds from sales and maturities of marketable securities
241,756
Purchase of property and equipment
481
Purchases of marketable securities
81,687
Purchase of in-process research and development
1,188
Net cash provided by (used in) investing activities
158,400
Proceeds from exercise of stock options
43
Net cash provided by financing activities
43
Net increase (decrease) in cash, cash equivalents and restricted cash
43,366
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sales and
maturities of marketable...
$241,756K
Proceeds from exercise of
stock options
$43K
Net cash provided by
(used in) investing...
$158,400K
Net cash provided by
financing activities
$43K
Canceled cashflow
$83,356K
Net increase
(decrease) in cash, cash...
$43,366K
Canceled cashflow
$115,077K
Purchases of marketable
securities
$81,687K
Purchase of in-process
research and development
$1,188K
Purchase of property and
equipment
$481K
Stock-based compensation
expense
$12,134K
Accrued restructuring
costs
$10,646K
Impairment of long-lived
assets
$10,197K
Accounts payable
$6,533K
Other non-current
assets
-$5,311K
Amortization of operating
lease right-of-use...
$1,080K
Depreciation
$712K
Acquired in-process
research and development
$665K
Prepaid expenses and
other current assets
-$316K
Net cash used in
operating activities
-$115,077K
Canceled cashflow
$47,594K
something is missing
-$134,435K
Accrued clinical and
research and development...
-$11,721K
Accrued expenses and
other current...
-$8,590K
Operating lease
liabilities
-$6,447K
Accretion on investments
in marketable...
$1,478K
Buy us a coffee
CARGO Therapeutics, Inc. (CRGX)
CARGO Therapeutics, Inc. (CRGX)